News

Aptahem AB develops drugs for the treatment of acute life-threatening conditions where Apta-1, the company’s main candidate, is under development and intended as an emergency drug to [...]

Aptahem can today announce that further studies with Örebro University on Apta-1 show strong evidence in its features on the coagulation and inflammation by a unique modulation of Thrombin. This [...]

Aptahem AB (publ) announces today that the company has received patent protection in USA for patent family 2 from the United States Patent and Trademark Office (USPTO). The approval follows the [...]

Aptahem AB (publ) announces today that the European Patent Office (EPO) has approved the EU patent application EP 18783424.7 entitled A nucleic acid molecule with anti-inflammatory and [...]

Aptahem AB (publ) announces today that the GLP (Good Laboratory Practice) toxicology and safety studies preliminary show positive results. The studies are the final part of the preclinical [...]

BioStock published an article on 12 July 2021 about Aptahem, which can be read in full below. During 2021, sepsis company Aptahem has taken several steps to prepare for its first clinical [...]

Aptahem AB (publ) announces today that the company has received information that the European Patent Office (EPO) has issued an Intention to Grant of the EU patent application EP 18783424.7 [...]

BioStock published an article on 1 July 2021 about Aptahem, which can be read in full below. Since 2019, Aptahem has collaborated with the Cardiovascular Research Centre (CVRC) at Örebro [...]

Aptahem AB (publ) announces today that the company has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance fo the US patent [...]

Aptahem AB (publ) announce today that the collaboration with the Cardiovascular Research Centre (CVRC) at Örebro University to map the details behind Apta-1’s effects with the support from the [...]